FDA has accepts for Priority Review Biologics License Application for tisotumab vedotin for treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy

Submission for this investigational antibody-drug conjugate specific for tissue factor, is based on innovaTV 204 phase 2 single-arm clinical trial (n=101) evaluating use as monotherapy in patients previously treated with doublet chemotherapy with or without bevacizumab.

Biospace Inc.